<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572334</url>
  </required_header>
  <id_info>
    <org_study_id>Eyhance Autorefraction study</org_study_id>
    <nct_id>NCT04572334</nct_id>
  </id_info>
  <brief_title>Eyhance Autorefraction Study</brief_title>
  <official_title>Repeatability of Post-operative Refraction in Patients With a Novel CE Marked Monofocal Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vienna Institute for Research in Ocular Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since 2018, the Tecnis Eyhance ICB00 lens (Johnson&amp;Johnson Vision, AMO Germany GmbH) was&#xD;
      introduced, which is a monofocal IOL which has the ability of extended depth of focus&#xD;
      improving intermediate vision without the photic phenomena specific for the multifocal IOLs.&#xD;
      The Tecnis Eyhance ICB00 is one of our standard IOL, routinely used in our clinic. There is&#xD;
      no single outcome measurement that can be thought of as summarizing the efficacy of an IOL,&#xD;
      nevertheless visual acuity and refractive outcome are the most important parameters for&#xD;
      evaluation. Aim of this study is to determine the comparability and reproducibility of&#xD;
      different refraction methods in patients implanted with Eyhance lens and compare the outcomes&#xD;
      with ZCB00 lens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a prospective observational study that would include pseudophakic patients that have&#xD;
      undergone cataract surgery 2 to 12 months prior. A written informed consent will be obtained&#xD;
      from each patient. Patients with ICB00 or ZCB00 implanted lenses will be included.&#xD;
&#xD;
      Autorefraction measurements will be performed consecutively, each patient will be measured&#xD;
      three times with each device. Two independent observers will perform subjective refraction&#xD;
      and will be masked to the autorefraction outcome.&#xD;
&#xD;
      We would like to include 50 eyes with ICB00 and 50 eyes with ZCB00 lens implanted. For the&#xD;
      estimation of sample size, we used data from Wang et al. (Wang L, Misra M, Palikaris IG, Koch&#xD;
      DD. J Cataract Refract Surg 2002; 28: 276-282) that compared the refractive outcome of&#xD;
      pseudophakic eyes and determined a mean spherical equivalent of -0.76 + 0.96 D for group I&#xD;
      and -0.44 + 1.13 for group II, thus leading to an effect size of 0.2. The effect size was&#xD;
      used for ANOVA test for repeated measurements within factor, with alpha &lt; 0.05, power of 80%&#xD;
      and a correlation of 0.5 between the two groups gave us an estimated of sample size of 42&#xD;
      patient. To allow patient drop out a number of 50 eyes will be included per lens group (in&#xD;
      total 100 eyes).&#xD;
&#xD;
      When different lenses are implanted (one eye received ZCB00 and the other Eyhance), than both&#xD;
      eyes of the patient will be included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reproducibility of different refraction methods</measure>
    <time_frame>2-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparability between the devices (autorefractometers)</measure>
    <time_frame>2-12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>visual acuity and refractive outcome for Tecnis Eyhance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>visual acuity and refractive outcome for Tecnis ZCB00</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Auto and Subjective Refraction</intervention_name>
    <description>All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction</description>
    <arm_group_label>visual acuity and refractive outcome for Tecnis Eyhance</arm_group_label>
    <arm_group_label>visual acuity and refractive outcome for Tecnis ZCB00</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  21 years old or above&#xD;
&#xD;
          -  Operated age-related cataract (pseudophakic patient)&#xD;
&#xD;
          -  Tecnis Eyhance ICB00 or Tecnis ZCB00 IOL implanted within 2 to 12 months prior to&#xD;
             study related examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intra- or Postoperative complication&#xD;
&#xD;
          -  patients with severe corneal pathology, severe macular degeneration, severe diabetic&#xD;
             retinopathy, etc. that would significantly influence visual outcome&#xD;
&#xD;
          -  nystagmus or pathologies that would affect patient fixation&#xD;
&#xD;
          -  pregnancy- for women in reproductive age a pregnancy test will be performed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oliver Findl, Prof., MD</last_name>
    <phone>+43 1 91021 57564</phone>
    <email>office@viros.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nino Hirnschall, MD, PhD</last_name>
    <phone>+43 1 91021 57564</phone>
    <email>nino.hirnschall@googlemail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hanusch Hospital, Department of Ophthalmology</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Findl, Prof. MD</last_name>
      <phone>+43 1 91021 57564</phone>
      <email>office@viros.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>October 3, 2020</last_update_submitted>
  <last_update_submitted_qc>October 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Head of the Ophthalmology Department, and Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

